25H-NBOMe

25H-NBOMe, identified as 2-(2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin, is expressly listed in Förteckning I of Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. The Government added it under Hallucinogener in Annex 1 to Förordning (1992:1554), and Läkemedelsverket placed it in Förteckning I; both measures took effect on 1 August 2013. Förteckning I covers substances, plant materials, and fungi that normally have no medical use. Under Narkotikastrafflag (1968:64), unauthorized transfer, production for abuse, acquisition for transfer, procurement, processing, packaging, transport, storage, possession, use, sale, and offering for sale are prohibited; unlawful import and export are separately governed by the smuggling statute.

25H-NBOMe is covered as a Class A drug by the generic structural provisions in Part I of Schedule 2 to the Misuse of Drugs Act 1971. It is 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine. Its 2,5-dimethoxyphenethylamine portion falls within paragraph 1(c), which covers phenethylamines bearing alkoxy ring substituents, and its N-(2-methoxybenzyl) substitution falls within paragraph 1(f), which covers a benzyl substituent on a paragraph 1(c) compound whether or not the benzyl phenyl ring is substituted. Paragraph 1(f) took effect on 10 June 2014, placing groups of NBOMe compounds under permanent Class A control. Possession, possession with intent to supply, production, supply, import, and export are prohibited except as permitted by applicable regulations, licences, or statutory defences.